Abiomed's heart pump gets EU nod
(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.
The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.
The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.
Impella cVAD is still not approved in the United States.
Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- Govt considers ban on e-cigarettes, sale of single smokes
- India's fiscal deficit in H1 almost 83 pct of full-year target
- Islamic State fighters kill 220 Iraqis from tribe that opposed them
- Muslim men over 50 pray at Jerusalem's Aqsa mosque amid tight security
- Europe won't recognise vote in eastern Ukraine, Merkel tells Putin
China will dispatch an elite unit from the People's Liberation Army to help Ebola-hit Liberia, the Foreign Ministry said on Friday, responding to U.N. calls for a greater global effort to fight the deadly virus in West Africa. Full Article
'Disastrous' health campaign feeds Pakistan's worrying polio spike. Full Article